Silence Therapeutics plc (SLN) research: valuation against peers, fundamentals over time, risk and news coverage
SLN
Silence Therapeutics plcNo data in this window.
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- BREAKING STORYBULLISHModerna Cancer-Vaccine Data Ignites Broad Biopharma Re-Rating
Moderna's cancer-vaccine breakthrough triggered a sector-wide rally in biopharma stocks, accelerating an upswing that had already begun to reverse years of underperformance. The data point revives the platform thesis for mRNA beyond infectious disease and pulls capital back toward clinical-stage names including smaller RNA-therapeutics developers.
- SPECIAL REPORTBEARISHInsider Selling Wave Sweeps Tech and Energy Leadership as Executives Monetise Elevated Valuations
A concentrated cluster of Form 4 disclosures showed Snowflake executives selling over $26m combined, Airbnb's CEO divesting $35m, and a LandBridge director unloading $93.8m. Simultaneously, Londian Wason priced a $94.3m IPO and Silence Therapeutics raised $175m, pointing to a supply-side response to elevated valuations and open capital markets.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.